Preclin Biosystems

Executive Summary

Preclin Biosystems AG is a Swiss preclinical contract research organization (CRO) founded in 2018, based in Zurich. The company provides a comprehensive in vivo testing platform specializing in chronic inflammatory and infectious disease models. Its services are fully customizable, focusing on mechanism of action, optimal administration routes, and efficacy for client therapeutic programs. As a private, pre-clinical stage company, Preclin Biosystems serves biotech and pharmaceutical clients seeking to validate lead candidates. While the company has not disclosed funding or valuation, its niche focus on inflammatory and infectious diseases positions it in a growing segment of the CRO market. The firm's success hinges on its ability to differentiate through specialized models and high-quality data, as well as expanding its client base beyond Swiss borders.

Upcoming Catalysts (preview)

• Q3 2026Expansion of disease model portfolio40% success
• Q1 2027Strategic partnership with a mid-sized pharma25% success
• Q4 2026Attainment of AAALAC accreditation50% success